2021 DORIS definition of remission in SLE: final recommendations from an international task force.
van Vollenhoven RF., Bertsias G., Doria A., Isenberg D., Morand E., Petri MA., Pons-Estel BA., Rahman A., Ugarte-Gil MF., Voskuyl A., Arnaud L., Bruce IN., Cervera R., Costedoat-Chalumeau N., Gordon C., Houssiau FA., Mosca M., Schneider M., Ward MM., Alarcon G., Aringer M., Askenase A., Bae S-C., Bootsma H., Boumpas DT., Brunner H., Clarke AE., Coney C., Czirják L., Dörner T., Faria R., Fischer R., Fritsch-Stork R., Inanc M., Jacobsen S., Jayne D., Kuhn A., van Leeuw B., Limper M., Mariette X., Navarra S., Nikpour M., Olesinska MH., Pons-Estel G., Romero-Diaz J., Rubio B., Schoenfeld Y., Bonfá E., Smolen J., Teng YKO., Tincani A., Tsang-A-Sjoe M., Vasconcelos C., Voss A., Werth VP., Zakharhova E., Aranow C.
OBJECTIVE: To achieve consensus on a definition of remission in SLE (DORIS). BACKGROUND: Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. METHODS: Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. RESULTS: Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. CONCLUSION: The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.